Welcome to our dedicated page for Cyclacel Pharma news (Ticker: CYCC), a resource for investors and traders seeking the latest updates and insights on Cyclacel Pharma stock.
Cyclacel Pharmaceuticals (CYCC) is a clinical-stage biopharmaceutical company pioneering targeted cancer therapies through cell cycle regulation. This resource provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access comprehensive coverage of CYCC's progress with its CDK and PLK inhibitor pipeline, including fadraciclib and plogosertib development. Stay informed about critical updates across multiple news categories: clinical trial results, regulatory filings, research collaborations, and intellectual property developments.
Our curated news collection enables efficient tracking of the company's precision medicine approach and therapeutic innovations in oncology. Regular updates ensure you never miss pivotal announcements about trial phases, partnership agreements, or scientific presentations.
Bookmark this page for streamlined access to verified CYCC developments. Check back frequently for objective reporting on advancements in targeted cancer treatment research and their implications for hematology/oncology care.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, NASDAQ: CYCCP) has completed enrollment of 12 patients in Cohort 8 of its Phase 2 study (065-101) of fadraciclib, a CDK2/9 inhibitor, for advanced solid tumors and lymphoma. This cohort focuses on patients with CDKN2A and/or CDKN2B abnormalities. Enrollment took approximately six months, highlighting the unmet medical need for this patient group.
The company reported stable disease and tumor shrinkage in a Phase 2 squamous cell cancer patient after two cycles of oral fadraciclib. Previously, a Phase 1 patient with squamous non-small cell lung cancer and CDKN2A/B abnormalities achieved a 22% reduction in tumor burden at 4 weeks.
Updated safety and efficacy data from the study will be presented at the upcoming 36th EORTC-NCI-AACR Symposium (ENA 2024, October 23-25, 2024). The Phase 2 study includes 8 cohorts, with Cohort 8 specifically targeting CDKN2A/B abnormalities, which occur frequently in various solid tumors.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company focused on developing innovative cancer medicines, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024, both virtually and in-person at the Lotte New York Palace Hotel in New York City.
Spiro Rombotis, President & CEO of Cyclacel, will present an overview of the company's business during the conference. Institutional investors can register for the event through the provided link or access the presentation via Cyclacel's investor relations website. The virtual presentations will be available on-demand starting September 9 at 7:00 A.M. (ET).
Cyclacel Pharmaceuticals (NASDAQ: CYCC) has filed an appeal against Nasdaq's delisting letter and requested a hearing before the Nasdaq Hearings Panel, scheduled for October 15, 2024. This action automatically stays any suspension or delisting pending the Panel's decision. The company was found non-compliant with Nasdaq Listing Rule 5550(b)(1) on August 26, 2024, as it reported stockholders' equity below $2.5 million as of June 30, 2024. At the hearing, Cyclacel will present its plan to regain and sustain compliance with the Equity Rule. However, there's no guarantee that the hearing will be successful or that the company will meet continued listing criteria if allowed to remain listed.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) reported its Q2 2024 financial results and provided a business update. Key highlights include:
1. The Phase 2 stage of the 065-101 study for oral fadraciclib is enrolling well, with interim data expected in Q4 2024.
2. Cash equivalents totaled $6.0 million as of June 30, 2024.
3. R&D expenses decreased to $2.0 million in Q2 2024 from $4.7 million in Q2 2023.
4. Net loss for Q2 2024 was $3.3 million, compared to $5.5 million in Q2 2023.
5. The company estimates its current cash resources will fund planned programs into Q4 2024.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company focused on developing innovative cancer medicines, has announced it will release its second quarter 2024 financial results on Wednesday, August 14, 2024. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day to discuss the results.
Investors and interested parties can access the conference call by dialing (800) 225-9448 (US) or (203) 518-9708 (international). The live webcast will be available on the Corporate Presentations page of Cyclacel's website. An audio replay will be accessible for 7 days, while the webcast will be archived for 90 days.
Cyclacel Pharmaceuticals announced it received a notice from the European Patent Office intending to grant a new patent for plogosertib pharmaceutical compositions. This patent will extend the exclusivity of plogosertib, a PLK1 inhibitor, until August 2040, excluding any extensions. The patent strengthens Cyclacel’s portfolio and supports a new oral formulation of plogosertib with improved bioavailability. Cyclacel aims to evaluate plogosertib for ARID1A- and/or SMARCA-mutated cancers. Additionally, its lead drug candidate, fadraciclib, is undergoing a proof-of-concept study in patients with solid tumors and T-cell lymphoma, with initial data expected in the second half of 2024.
Cyclacel Pharmaceuticals announced preclinical data for fadraciclib, a CDK2/9 inhibitor, demonstrating efficacy in metastatic colorectal cancer (CRC) models. Presented at the 2024 ASCO Annual Meeting, the study showed that fadraciclib significantly inhibited tumor growth, induced apoptosis, and triggered anaphase catastrophe in CRC patient-derived organoids (PDOs) and xenografts (PDXs). The research highlighted fadraciclib's superiority over standard chemotherapy and palbociclib in CRC models. Cyclacel's CEO, Spiro Rombotis, emphasized fadraciclib’s broad potential in multiple tumor types. Initial proof of concept data is expected in the second half of 2024.
Cyclacel Pharmaceuticals presented new clinical data on their CDK2/9 inhibitor, fadraciclib, at the 2024 ASCO Annual Meeting. The Phase 1 study, CYC065-101, involved heavily pretreated patients with various cancers, demonstrating clinical benefits in endometrial, lung, ovarian, pancreatic cancers, and T-cell lymphoma. Fadraciclib showed good tolerance with the most common adverse events being nausea, vomiting, and diarrhea. Pharmacokinetic (PK) and pharmacodynamic (PD) data indicated dose proportionality and efficacy in CDKN2A/B suppression. The Phase 2 proof of concept part is currently enrolling patients with CDKN2A/B loss or T-cell lymphoma, with initial results expected in the second half of 2024.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) reported its first quarter 2024 financial results and provided a business update. Key highlights include enrolling patients in the Phase 2 proof-of-concept (PoC) study of oral fadraciclib, a CDK2/9 inhibitor, with data to be presented at the ASCO Annual Meeting. The company received $8.0 million from a private placement, bolstering its balance sheet. As of March 31, 2024, Cyclacel had $9.9 million in pro forma cash and cash equivalents, including $0.8 million from the UK R&D tax credit. The net loss for Q1 2024 was $2.9 million, a decrease from $5.8 million in Q1 2023. R&D expenses were $2.8 million compared to $5.7 million last year. The company plans to report key data from its ongoing clinical trials later this year.
Cyclacel Pharmaceuticals, Inc. will release its first quarter 2024 financial results on May 14, 2024. The company focuses on developing innovative cancer treatments and will host a conference call and webcast to discuss the results.
